Sign up to save your podcasts
Or
Share Let’s Talk Compliance: What the July 3rd Ruling on FTC Non-Compete Ban Means for the Health Care Industry
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Let’s Talk Compliance: What the July 3rd Ruling on FTC Non-Compete Ban Means for the Health Care Industry
In this episode, Benjamin Dryden, vice chair of Foley’s Antitrust & Competition Practice Group and David McMillan, managing principal of consulting and chief financial officer at PYA, discuss the recent July 3rd ruling on the U.S. Federal Trade Commission’s (FTC) Non-compete Ban and how this will affect the health care & life sciences industry.
View all episodes
By Foley & Lardner LLP
4.8
88 ratings
In this episode, Benjamin Dryden, vice chair of Foley’s Antitrust & Competition Practice Group and David McMillan, managing principal of consulting and chief financial officer at PYA, discuss the recent July 3rd ruling on the U.S. Federal Trade Commission’s (FTC) Non-compete Ban and how this will affect the health care & life sciences industry.